Zoek in het archief
 
terug

Check the original
News breaking: 2017-12-01

Takeda benoemt Toshio Fujimoto tot algemeen directeur Health Innovation Park in Shonan

OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (TSE: 4502) heeft vandaag bekendgemaakt dat Toshio Fujimoto is benoemd tot algemeen directeur van het Health Innovation Park in Shonan. De benoeming treedt 1 december 2017 in werking. Uit hoofde van zijn nieuwe functie is de van Eli Lilly overgekomen dr. Fujimoto verantwoordelijk voor strategisch bestuur en leiding aan alle kernactiviteiten van het Park, waaronder: ontwikkeling en uitvoering van zakelijke en financiële plannen, coördinatie van werkzaamheden op het terrein, werving van huurders, marketing en public relations. Dr. Fujimoto rapporteert aan een nieuw opgerichte directieraad, bestaande uit bestuurders van Takeda. De directieraad staat onder leiding van voorzitter Seigo Izumo (Internationaal hoofd regeneratieve geneeskunde, Hoofd wetenschappelijke zaken, Japan) en bestaat verder uit Salvatore Alesco (Hoofd Onderzoek & Ontwikkeling Internationaal en Biomedisch beleid) en Haruhiko Hirate (Corporate officer, hoofd communicatie en hoofd Public Affairs). De directieraad geeft advies en ondersteuning bij het opzetten van het Park en het aangaan van betekenisvolle samenwerkingen met academische instituties, bedrijven in biotech en biofarmacie en andere partners.

 

Takeda Appoints Toshio Fujimoto, MD, MBA, as General Manager of the Health Innovation Park in Shonan

OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited TSE: 4502 announced today that Toshio Fujimoto, MD, MBA has been appointed General Manager of the Health Innovation Park in Shonan. The appointment is effective as of December 1, 2017. In this new role, Dr. Fujimoto, who joins Takeda from Eli Lilly Japan, will provide strategic leadership and oversight for all key Park activities, including: development and execution of business and financial plans, coordination of site operations and services, tenant recruitment and management, and marketing and public relations activities. Dr. Fujimoto will be accountable to a newly formed Management Board comprised of Takeda executives. The Management Board will be led by Seigo Izumo (Global Head of Regenerative Medicine Unit, Head of Scientific Affairs, Japan), who will serve as Chair, and will include Salvatore Alesci (Head of R&D Global Science and Biomedical Policy) and Haruhiko Hirate (Corporate Officer, Corporate Communications and Public Affairs Officer). The Management Board will provide counsel and support decision-making as Takeda continues to establish the Park’s ecosystem and maintain efforts to build meaningful collaborations with academic institutions, biotech and biopharmaceutical companies and other partners.

Dr. Fujimoto brings to Shonan diverse R&D experience, strong leadership skills and business acumen. In his most recent role as Vice President, Medicine Development Unit at Eli Lilly Japan – a position which he held since 2015, he oversaw the R&D Management function in Japan. Dr. Fujimoto received his MD from Kyoto University and his MBA from Kobe University. He began his clinical practice as a Resident in the Department of Thoracic Surgery at Kyoto University Hospital. After completing several rotations at local area hospitals, he took a position in Germany as Assistant Surgeon with the Thoracic Surgery Department at Ruhrlandklink Hospital, and later moved to the U.S. to serve as Clinical Fellow, General Thoracic Surgery at the Mayo Clinic.

“The appointment of Dr. Fujimoto as General Manager of our Health Innovation Park is an important milestone that signals to both our current and prospective partners, our continued commitment to promote an open innovation ecosystem in Japan,” said Andrew Plump, Chief Medical and Scientific Offer, Takeda. “I have every expectation that Dr. Fujimoto’s passion, leadership skills and R&D experience will be a tremendous asset in our efforts to build a vibrant and exciting community for industry, government and academia to incubate and accelerate the translation of cutting-edge science into impactful healthcare solutions for patients in Japan – and across the globe. I am excited to welcome him to our executive team.”

Takeda has committed significant resources to the development of its Health Innovation Park in Shonan as the Company seeks to establish the first openly innovative ecosystem built on pharmaceutical know-how in Japan.

Shonan Health Innovation Park Partners (as of 1st December)

T-CiRA

Axcelead Drug Discovery Partners, Inc.

Scohia, Inc.

Cardurion Pharmaceuticals.

Seedsupply, Inc.

ChromaJean, Inc.

Chordia Therapeutics, Inc.

Rabics, Inc.

K-Pharma, Inc.

Noile-Immune Biotech, Inc.

Oita University

Institute of Advanced Medicine, Inc.

For more information about Takeda’s Innovation Ecosystem, visit Ecosystem for health innovation.

For more information about Shonan Health Innovation Park, visit shonan-health-innovation-park.com.

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in Emerging Markets, are currently fueling the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries. For more information, visit www.takeda.com/news.

Takeda’s Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements include all statements other than statements of historical fact, including plans, strategies and expectations for the future, statements regarding the expected timing of filings and approvals relating to the transaction, the expected timing of the completion of the transaction, the ability to complete the transaction or to satisfy the various closing conditions, future revenues and profitability from or growth or any assumptions underlying any of the foregoing. Statements made in the future tense, and words such as “anticipate,” “expect,” “project,” “continue,” “believe,” “plan,” “estimate,” “pro forma,” “intend,” “potential,” “target,” “forecast,” “guidance,” “outlook,” “seek,” “assume,” “will,” “may,” “should,” and similar expressions are intended to qualify as forward-looking statements. Forward-looking statements are based on estimates and assumptions made by management that are believed to be reasonable, though they are inherently uncertain and difficult to predict. Investors and security holders are cautioned not to place undue reliance on these forward-looking statements.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Some of these risks and uncertainties include, but are not limited to: required regulatory approvals for the transaction may not be obtained in a timely manner, if at all; the conditions to closing of the transaction may not be satisfied; competitive pressures and developments; applicable laws and regulations; the success or failure of product development programs; actions of regulatory authorities and the timing thereof; changes in exchange rates; and claims or concerns regarding the safety or efficacy of marketed products or product candidates in development. The forward-looking statements contained in this press release speak only as of the date of this press release, and neither Portal Instruments nor Takeda undertake any obligation to revise or update any forward-looking statements to reflect new information, future events or circumstances after the date of the forward-looking statement. If one or more of these statements is updated or corrected, investors and others should not conclude that additional updates or corrections will be made.

 

 

View source version on businesswire.com: http://www.businesswire.com/news/home/20171130006314/en/

Contacts

Takeda Pharmaceutical Company Limited

Tatsuhiro Kanoo – Japan

Tatsuhiro.kanoo@takeda.com

+81 (0) 3-3278-3634

or

Kelly Schlemm – USA

kelly.schlemm@takeda.com

+1-617-551-8865

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.